Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Lipoic Acid for Neuroprotection in Secondary Progressive MS
Sponsor: Oregon Health and Science University
A PHASE2/PHASE3 clinical study on Multiple Sclerosis, Chronic Progressive, this trial is completed. The trial is conducted by Oregon Health and Science University and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oregon Health and Science University
- VA Office of Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .